Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and other cloud technology to accelerate breakthroughs in cancer. Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
In keeping with MSK’s mission of Ending Cancer for Life, AWS will provide the advanced tools and technology for MSK to unlock insights derived from years of clinical research and cancer treatment. This groundbreaking effort will incorporate deidentified genomic, imaging, and clinical data to create a powerful source for MSK’s AI driven cancer research and personalized treatment development. The goal will be to build a high-quality, up-to-date longitudinal data resource for cancer research at MSK, as well as serve as a source for validating and improving cancer research with partners.
“MSK’s collaboration with AWS is rooted in our shared vision and commitment to accelerate the pace with which we ideate, create, and bring lifesaving innovations to cancer patients. A critical enabler of this will be harnessing the scale and expertise of the larger Amazon organization to advance our processes and infrastructure related to AI, inclusive of large language models.” said MSK Chief Strategy Officer Dr. Anaeze Offodile II.
With support from AWS, MSK also aims to expand its Innovation Hub, its startup ecosystem, and its AI-enabled drug discovery efforts. Learn more about this exciting new collaboration here.